PATIENT INFORMATION							
MDSS Investigation ID		Age (years)	Male Female				
Date of TB suspicion/diagnosis		Date referred to LH	D				
Referred by	(name)		(organization)				
Employment status							
	CLINICAL INF	ORMATION					
	Risk Factors &	Co-morbidities	None reported				
Born in a WHO TB high	burden country*	Contact to a TB ca	ase (<u><</u> 2 years prior)				
Born outside of the US	(other than above)	History of contact	History of contact to TB case (> 2 years prior)				
Travel to a WHO TB hig	h burden country*	History of positive	e TB test				
Travel outside of the U	S (other than above)	Previous diagnosi	S -				
COPD		History of treatme	ent -				
Diabetes Mellitus		History of partial	treatment -				
End-stage renal disease		Correctional facili	ty -				
Viral hepatitis –		Healthcare facility -					
Reported history of res	piratory diagnoses	Smoking -					
Pregnancy		Vaping -					
Post-organ transplanta	tion	Homelessness -					
TNF-α antagonist thera	ру	Substance use -					
HIV-infected		Excess alcohol use -					
Immunosuppression (or	ther than HIV)	Unknown					
Other							
	Sym	otoms	None reported				
Approximate start date							
Night sweats	Productive cough	Non-pr	oductive cough				
Chest pain	SOB	Hemop	tysis				
Fatigue	Fever	Uninter	ntional weight loss				
Eye or vision issues	Lymph node swel	ling Joint pa	ain				
Unknown	Other						
	Site(s) of						
	Pulmonary Extrapulmonary		ary and extrapulmonary				
Ruled out pulmonary disease?		Yes	No				
	Clinical	Notes					

*WHO 30 High TB Burden Countries: https://www.who.int/tb/publications/global_report/tb19_Report_country_profiles_15October2019.pdf?ua=1

		TREAT	MENT		Not started	
Treatment start date		Estimated end date				
		Initiation	Phase			
Regimen: RIP	E Other					
Dosing frequency (# dos	ses/week)		Initiation phase	completion dat	te	
		Continuatio	on Phase		Not started	
Regimen: INH	I/RIF Other					
Dosing frequency (# dos	ses/week)					
Treatment completed:	Yes	No	Completion date			
		Medication Ad	ministration			
# of in-person DOT dos	ses		# of SAT doses			
eDOT used: Yes Program used for eDO ⁻		eDOT	doses counted as:	DOT	SAT	
	Not Finishi	ng Treatment/F	- inishing Treatmen	t Early	N/A	
Adverse drug eve	nt Non-a	Idherent	Patient died/	dying F	Patient choice	
Clinically indicate	d Not T	В	Patient lost	ι	Jnknown	
Treatment failure	Drug	resistance	Other			
		Adverse D	rug Events		None reported	
Arthralgias	Fatigue, mala	ise Itc	hiness, rash	Neuropathy	Fever	
Jaundice, dark uri Other	ine Blurred,	changed vision	Nausea, vo	omiting, anorexi	a, abdominal pain	
INH RII	F EMB	PZA	Other			
		Treatmer	nt Notes			

CLINICAL & SOCIAL BARRIERS					
Barrier	Intervention atte	empted		Notes	
Co-morbidities	Y	Ν			
Pediatric	Υ	Ν			
Medication management	Y	Ν			
Adverse drug events	Υ	Ν			
Paradoxical reaction	Υ	N			
Symptoms worsening or unresolved	Υ	N			
Referrer	Υ	N			
Medical management	Υ	Ν			
Specimen collection	Υ	Ν			
Lab result interpretation	Υ	Ν			
DOT	Υ	Ν			
Medication supply	Υ	Ν			
Smoking, vaping, substance or alcohol use	Υ	N			
Mental illness	Y	Ν			
Patient cooperation, support	Υ	Ν			
Family cooperation, support	Υ	N			
Children (in home, family)	Y	Ν			
Religion, culture	Υ	Ν			
Language, literacy	Υ	Ν			
Suspected trafficking	Υ	Ν			
Other:	γ	N			

	ECON	OMIC BARRIERS	None reporte	ed	
Barrier	Intervention a	attempted	Notes		
Food insecurity	Y	N			
Homelessness, shelter insecurity	Y	Ν			
Transportation	Y	N			
Employment insecurity, unable to work	Y	Ν			
Uninsured, underinsured	Y	Ν			
Other:	Y	Ν			
	INCENT	IVES & ENABLER	S Not use	ed	
	So	urce of Funds			
MDHHS	Staff (individu	ally or collectively)	LHD from TB or other funds		
Unknown	Other				
stimated amount spent: \$					
		Туре			
Hotel, rent paid	Medical bills paid		Energy, gas, electric bills paid		
Fast food gift cards	Food, grocery gift cards		Gas cards, bus passes, taxis		
Clothing, hygiene items	Unknown Other				
		Purpose			
Appreciation	Compliance	e, DOT	End of treatment, congratulations		
Children (in home, family)	Contact inv	estigation	LTBI treatment, window prophylax		
Malnourishment	Worsening TB symptoms		Side-effects from treatment		
Quarantine, restrictions	Uninsured, underinsured		Unemployed, unable to work		
Food insecurity	Transportation insecurity		Assistance with monthly bills		
Phone, communication	Shelter insecurity		Essentials (clothing, hygiene items, etc.,		
Cost of care to LHD	Unknown	Other			
	B	arrier Notes			

CONTACT INVESTIGATION							CI not done		
Reason for conducting contact investigation (if applicable)									
Sputum Smear +	Sputum Smear -/Culture +			Otł	Other Respiratory Culture +				
Culture - /Abnormal Imaging	Only Res	spiratory Symp	otoms	Otł	Other				
	Contac	t Investigation	Results						
	Household	Other Family	Work	School	Social	HCW	Other	TOTAL	
Identified									
Evaluated									
Refused evaluation									
Lost to follow-up (evaluation)									
TST/IGRA positive									
Previous disease or previous positive									
Lost to follow-up (diagnosis)									
Diagnosed: active disease									
Diagnosed: LTBI									
Started LTBI treatment									
Refused LTBI treatment									
Lost to follow-up (LTBI treatment)									
Currently on LTBI treatment									
Discontinued LTBI treatment									
Died before completing LTBI tx									
Completed LTBI tx									
				1					
Were any children started on window prophylaxis? Yes No If yes, how many? Contact Investigation Notes (including LTBI treatment notes) If yes, how many?									
	investigatior	i Notes (Includ	ING LI BI	treatmen	t notes)				

CONTACT INVESTIGATION BARRIERS None reported						
Barrier	Intervention a	attempted	Notes			
Language, literacy	Y	Ν				
Religion, culture	Y	Ν				
Uncooperative contacts	Y	Ν				
Uncooperative patients	Y	Ν				
LTBI regimen supply	Y	Ν				
LTBI treatment adherence	Y	Ν				
Other:						
Notes						